scholarly article | Q13442814 |
P356 | DOI | 10.1097/JCP.0B013E31825CCDE5 |
P698 | PubMed publication ID | 22722504 |
P2093 | author name string | Ilise Lombardo | |
Sheela Kolluri | |||
Gary Sachs | |||
Ruoyong Yang | |||
Charlotte Kremer | |||
P433 | issue | 4 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | placebo | Q269829 |
P304 | page(s) | 470-478 | |
P577 | publication date | 2012-08-01 | |
P1433 | published in | Journal of Clinical Psychopharmacology | Q6294969 |
P1476 | title | Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? | |
P478 | volume | 32 |
Q38090854 | A systematic review of the evidence for the treatment of acute depression in bipolar I disorder |
Q34475987 | Antipsychotics as antidepressants |
Q38297860 | Balancing benefits and harms of treatments for acute bipolar depression |
Q38297855 | Current landscape, unmet needs, and future directions for treatment of bipolar depression |
Q36588607 | Evidence review and clinical guidance for the use of ziprasidone in Canada |
Q46300154 | Guidelines for the recognition and management of mixed depression |
Q38507842 | Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat |
Q34515834 | LURASIDONE IN THE LONG-TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24-WEEK OPEN-LABEL EXTENSION STUDY |
Q39164212 | Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis |
Q38297863 | Managing the side effects associated with commonly used treatments for bipolar depression |
Q38342840 | Non-pharmacological strategies for treatment of inpatient depression |
Q89665746 | Personalized Pharmacotherapy for Bipolar Disorder: How to Tailor Findings From Randomized Trials to Individual Patient-Level Outcomes |
Q34349641 | Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis |
Q26747670 | Pharmacotherapy of Acute Bipolar Depression in Adults: An Evidence Based Approach |
Q36017024 | Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments |
Q39013963 | Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials |
Q28066714 | The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm |
Q38931913 | The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years |
Q38697937 | The development of lurasidone for bipolar depression |
Q38208032 | The effectiveness of lurasidone as an adjunct to lithium or divalproex in the treatment of bipolar disorder |
Q38269372 | Treatment of bipolar depression: making sensible decisions |
Search more.